BMN 110 US Expanded Access Program
NCT01858103 · Status: APPROVED_FOR_MARKETING · Type: EXPANDED_ACCESS
Last updated 2014-04-02
Summary
The Expanded Access Program (EAP) is an open-label, multicenter program to:
1. Provide patients who have been diagnosed with Mucopolysaccharidosis IVA (MPS IVA) access to BMN 110 until commercial product is available
2. Collect additional information on the safety and tolerability of BMN 110 administration in patients with MPS IVA
Patients enrolled in the EAP will receive 2.0 mg/kg intravenous infusions of BMN 110 every week during the program.
Conditions
- Mucopolysaccharidosis IVA
- Morquio A Syndrome
- MPS IVA
Interventions
- DRUG
-
BMN 110
Sponsors & Collaborators
- lead INDUSTRY
Eligibility
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
Countries
- United States
- Puerto Rico
Study Locations
More Related Trials
-
Study of BMN 110 in Pediatric Patients < 5 Years of Age With Mucopolysaccharidosis IVA (Morquio A Syndrome)
NCT01515956 ·Status: COMPLETED ·Phase: PHASE2
-
BMN 110 Phase 3B in Australian Patients
NCT01966029 ·Status: COMPLETED ·Phase: PHASE3
-
A Open Label Study in Previously Studied, SBC-103 Treatment Naïve MPS IIIB Subjects to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics/Efficacy of SBC-103 Administered Intravenously
NCT02618512 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
New Imaging Technology to Assess Effect of Enzyme Replacment Therapy on Eye Disease Progession in Mucopolysacchardiosis
NCT02583152 ·Status: UNKNOWN
-
A Long-term Follow-up Study of Patients With MPS IIIB Treated With ABO-101
NCT04655911 ·Status: TERMINATED
-
A Clinical Assessment Study of Subjects With Mucopolysaccharidosis IVA (Morquio Syndrome)
NCT00787995 ·Status: TERMINATED
-
Gene Transfer Clinical Trial for Mucopolysaccharidosis (MPS) IIIB
NCT03315182 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Gene Transfer Study of ABO-102 in Patients With Middle and Advanced Phases of MPS IIIA Disease
NCT04088734 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
A Treatment Extension Study of Mucopolysaccharidosis Type IIIB
NCT03784287 ·Status: UNKNOWN ·Phase: PHASE2
-
A Treatment Study of Mucopolysaccharidosis Type IIIB
NCT02754076 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
AAV Gene Therapy Study for Subjects with PKU
NCT04480567 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Safety/Tolerability/Pharmacokinetic (PK)/Pharmacodynamics (PD) Study of BMN701 in Patients With Late-Onset Pompe Disease
NCT01230801 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Study of Recombinant Human N-Acetylgalactosamine 4-Sulfatase in Patients With MPS VI
NCT00048620 ·Status: COMPLETED ·Phase: PHASE1
-
Observational Study of Patients With Mucopolysaccharidosis (MPS) VI Who Previously Participated in ASB-00-02
NCT01387854 ·Status: COMPLETED
-
Tideglusib: Expanded Access Use in Congenital Myotonic Dystrophy
NCT07119775 ·Status: AVAILABLE
-
Mucopolysaccharidosis (MPS) VI Clinical Surveillance Program (CSP)
NCT00214773 ·Status: COMPLETED
-
Open-Label Study of Efficacy and Safety of Recombinant Human N-acetylgalactosamine 4-sulfatase in Patients With MPS VI
NCT00048711 ·Status: COMPLETED ·Phase: PHASE2
-
Ascending Dose Study of Genome Editing by the Zinc Finger Nuclease (ZFN) Therapeutic SB-318 in Subjects With MPS I
NCT02702115 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Safety, Pharmacokinetics, and Pharmacodynamics/Efficacy of SBC-103 in Mucopolysaccharidosis III, Type B (MPS IIIB)
NCT02324049 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Follow-up Study of AAV-Mediated Gene Transfer (UX111; Previously Known as ABO-102) for MPS Type IIIA
NCT04360265 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE3
-
Phase I/II/III Gene Transfer Clinical Trial of scAAV9.U1a.hSGSH
NCT02716246 ·Status: RECRUITING ·Phase: PHASE2/PHASE3
-
Natural History Study of Patients With Mucopolysaccharidosis Type IIIB (MPS IIIB, Sanfilippo Syndrome Type B)
NCT01509768 ·Status: COMPLETED
-
A Phase 1/2 Open-Label Dose-Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of Intracerebroventricular BMN 190 in Patients With Late-Infantile Neuronal Ceroid Lipofuscinosis (CLN2) Disease
NCT01907087 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Multicenter, Multi-national Open-label Program to Provide BMN 190 to Patients Diagnosed With CLN2 Disease
NCT02963350 ·Status: APPROVED_FOR_MARKETING
-
Safety, Tolerability and Efficacy of ICV AX 250 Treatment in MPS IIIB -OLE
NCT05492799 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE4